Rodent-borne hantaviruses are etiologic agents for hemorrhagic fever with renal syndrome and hantavirus cardiopulmonary syndrome in the Old World and New World, respectively. These often severe diseases are relatively uncommon in most parts of the world and are sufficiently genetically variable that widely cross-protective vaccines will probably need to be polyvalent. The current status of hantavirus vaccines shall be reviewed and both conventional and speculative new vaccine technologies that may evolve within the field shall be considered.